Sankyo/Cygnus settlement
This article was originally published in The Gray Sheet
Executive Summary
Sankyo Pharma agrees to pay $30 mil. to dissolve an agreement to distribute Cygnus' GlucoWatch G2 Biographer diabetes monitors in the U.S., companies announce Dec. 23. The settlement requires Sankyo to provide transition services related to product distribution for six months and to give Cygnus the title to its remaining inventory of GlucoWatch products, approximately 20,000 G2 Biographers and 1 mil. AutoSensors.Cygnus had sued Sankyo for breach of contract and laid off 60% of its workforce, following Sankyo's decision to terminate the deal (1"The Gray Sheet" Nov. 17, 2003, In Brief). Cygnus notes it is in discussions with potential distributors...
You may also be interested in...
Cygnus mulling GlucoWatch sale
Non-invasive glucose monitor maker is considering the sale of "some or all" of its assets, among other options, to meet debt obligations and continue operations. The move would follow distributor Sankyo's decision not to honor previous purchase commitments through March 2004, Cygnus says (1"The Gray Sheet" Oct. 13, 2003, p. 17). On Nov. 6, Sankyo countered Cygnus' Oct. 6 breach-of-contract suit, citing defamation and breach of contract and seeking declaratory relief. As of Sept. 30, Cygnus had $9.1 mil. in cash and total liabilities of $81.5 mil. On Nov. 13, the firm reported a Q3 loss of $9.1 mil. on sales of $1.1 mil. (down 31%). Sankyo already has about two years' inventory, "so we anticipate they will continue to [make] the product available for an extended period," Cygnus says...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.